Professional Webinars | Aplastic Anemia & MDS International Foundation Return to top.

Professional Webinars

For a full list of our upcoming conferences for health care professionals see: Professionals » Professional Conferences.

CE Accreditation Period: 03/10/2022 to 03/17/2023
Topic(s): Myelodysplastic Syndromes (MDS)

Those are some of the practice-changing conclusions of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1102 study of older patients with high-risk MDS. Our panel of experts will delve into the implications for your practice during a 60-minute roundtable webinar on Thursday, March 17, at 11:30 a.m. CDT. 

You'll walk away from the webinar with a better understanding of:
• The BMT CTN 1102 study—a multicenter, biologic assignment trial in older patients with high-risk MDS to define the benefit of hematopoietic cell transplant (HCT) over non-HCT therapy
•  How quality of life and functional performance status are better than age in determining eligibility for HCT
• How advances in HCT facilitate improved survival and preserve quality of life
• What these findings mean for community hematologists/oncologists who see patients with MDS
• Best practices for referring patients to a transplant center early for HCT consultation
The Medical College of Wisconsin designates this Virtual Activity for a maximum of 1 AMA PRA Category 1 Credit(s) ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CE Accreditation Period: 01/17/2022 to 01/17/2024
Topic(s): Related Bone Marrow Failure Diseases and Malignancies, Pediatric Bone Marrow Failure Diseases, Paroxysmal Nocturnal Hemoglobinuria (PNH), Bone Marrow Transplant, Aplastic Anemia, Living Well with Bone Marrow Failure, Myelodysplastic Syndromes (MDS), Managing Your Treatment, Acute Myeloid Leukemia (AML)

We are excited to announce a complimentary, CME-certified on-demand webcast series Resuscitating a Dying Marrow: Emerging Concepts and Treatment Advances in Myeloid Malignancies.  This enduring material was recorded during the Virtual Friday Satellite Symposium held on December 10th, 2021 preceding the 63rd Annual ASH Meeting and Exposition.

This program is jointly sponsored by the Cleveland Clinic and the Aplastic Anemia and MDS International Foundation, and it brings together international leaders in disease research and clinical practice.

 We are honored to be joined by the following prestigious faculty:

  • Dr. Antonio Risitano of A.O.R.N MOSCATI in Avelino, Italy summarizes new frontiers in PNH.
  • Dr. Yogen Saunthararajah of Cleveland Clinic in Cleveland, Ohio covers low-risk and high-risk MDS.
  • Dr. Naveen Pemmaraju of The University of Texas MD Anderson Cancer Center in Houston, Texas shares updates on chronic MPN.
  • Dr. Seth J. Corey of Cleveland Clinic in Cleveland, Ohio presents on germline pre-disposition to myeloid malignancies.
  • Dr. Gert Ossenkoppele of Amsterdam University Medical Centers in The Netherlands identifies molecular targets for personalized treatment of AML.
  • Dr. Mark Juckett of the University of Minnesota Medical School in Minneapolis, Minnesota describes the treatment of older MDS with BMT.

In addition, Dr. Bhumika Patel and Dr. Sudipto Mukherjee lead two interactive case-based discussions with audience participation and questions for the faculty. 

Join us as we explore Resuscitating a Dying Marrow: Emerging Concepts and Treatment Advances in Myeloid Malignancies.

CE Accreditation Period: 06/15/2021 to 06/14/2022
Topic(s): Myelodysplastic Syndromes (MDS)

The Spectrum of MDS: Disease Management and Patient Education

The symposium was presented through the ONS Bridge platform on Thursday April, 29th targeted to clinical nursing professionals in oncology. Case studies were used to illustrate treatment decision-making and therapeutic challenges.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Explain the methods used to diagnose, stratify and treat MDS
  • Identify current and emerging treatment options for patients with low-risk MDS, high-risk MDS, and secondary AML
  • Analyze the nurse's role in managing treatment for MDS based on clinical presentations, diagnostic workups, transfusion dependence, comorbidities, and clinical trial consideration
  • Discuss strategies to address treatment goals and decision-making, educate patients and provide palliative care to improve outcomes

Target Audience

This activity is intended for nurses and nurse practitioners engaged in the care of patients withMyelodysplastic Syndromes(MDS).

CE Accreditation Period: 12/04/2020 to 01/01/2023
Topic(s): Related Bone Marrow Failure Diseases and Malignancies, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML)

This Satellite Symposium, which preceded the 61st ASH Annual meeting, was organized by the Cleveland Clinic Taussig Cancer Institute Leukemia Program and the Aplastic Anemia and MDS International Foundation.

The complementary enduring program provides an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with myeloid malignancies including aplastic anemia, paroxysmal nocturnal hemoglobinuria, MDS, AML, MPN and related myeloid malignancies. This program brought together leaders in disease research and clinical practice to explore solutions to improving the care of these patient populations.

Share with